Ferring Pharmaceuticals has signed an agreement to acquire Gameto, a fertility startup. The deal could be worth up to $1.3825 billion, according to the companies.
Endpoints News reported the agreement, describing Gameto as an ovary-in-a-dish startup in its headline. The report's opening paragraph states that Ferring signed the agreement and that the deal could be worth up to $1.3825 billion. Ryan Cross, senior science correspondent at Endpoints News, wrote the report.
The acquisition would bring Gameto under Ferring, according to the report. The headline said the deal was for up to $1.38 billion, while the opening paragraph said $1.3825 billion. The report did not name an investor or a closing date. Further financial terms were not specified in the portion of the article available. The source did not include a valuation. The available text of the source ends mid-sentence after the words "the companies." Endpoints News did not state when the deal is expected to close.
Sources
To report an error in this article, write to corrections@venturistnews.com. Corrections log.
Nina Castell covers startups, funding rounds and acquisitions for Venturist. She writes from company announcements, filings and published reporting.